The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase I/Ib study of olaparib and ASTX727 in BRCA 1/2- and HRD-mutated tumors.
 
Pamela Munster
Leadership - Alessa Therapeutics
Stock and Other Ownership Interests - Alessa Therapeutics; AtlasMedx; Hap10; OnKure; Parthenon Therapeutics; RasCal
Honoraria - JNJ; Olema Pharmaceuticals; Parthenon Therapeutics
Consulting or Advisory Role - Alessa Therapeutics; AtlasMedx; Olema Pharmaceuticals; RasCal
Research Funding - Actuate Therapeutics (Inst); Amgen (Inst); Arch Oncology (Inst); Arvinas (Inst); Arvinas (Inst); Bliss Biopharmaceutical (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Cyteir; Deciphera (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); IgM Biosciences (Inst); Immune Design (Inst); InventisBio (Inst); Merck (Inst); Novartis (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); PMV Pharma (Inst); Relay Therapeutics (Inst); Revolution Medicines (Inst); Sanofi (Inst); Seagen (Inst); Skorpion (Inst); Tempest Therapeutics (Inst); Xencor (Inst); Xynomic Pharma (Inst)
Patents, Royalties, Other Intellectual Property - UCSF patent on using silastic implants to deliver anticancer agents
Other Relationship - ABIM Subspecialty Board; NIH/NCI
 
Robin Kate Kelley
Consulting or Advisory Role - Agios (Inst); AstraZeneca (Inst); Compass Therapeutics; Elevar Therapeutics; Exelixis/Ipsen (Inst); GlaxoSmithKline; J-Pharma; Jazz Pharmaceuticals; Kinnate Biopharma; Merck (Inst); Moderna Therapeutics; Regeneron; Tyra Biosciences
Research Funding - Adaptimmune (Inst); Agios (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Compass Therapeutics (Inst); EMD Serono (Inst); Exelixis (Inst); Genentech/Roche (Inst); Lilly (Inst); Loxo/Lilly (Inst); MedImmune (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Partner Therapeutics (Inst); QED Therapeutics (Inst); Relay Therapeutics (Inst); SERVIER (Inst); Surface Oncology (Inst); Taiho Pharmaceutical (Inst); Tyra Biosciences (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Merck; Merck
 
Susan Calabrese
No Relationships to Disclose
 
Kelli Walker
No Relationships to Disclose
 
Ethan Clark
No Relationships to Disclose
 
Phu Lam
No Relationships to Disclose
 
Savannah Berkley
No Relationships to Disclose
 
Scott Thomas
Employment - Alessa Therapeutics; Genentech/Roche (I)
Stock and Other Ownership Interests - Alessa Therapeutics
Consulting or Advisory Role - Alessa Therapeutics
Patents, Royalties, Other Intellectual Property - Received royalties associated with Patents filed in conjunction with UCSF.
 
Varun Monga
Honoraria - Binacea
Consulting or Advisory Role - Atheneum
Research Funding - InhibRx (Inst); Nested Therapeutics (Inst); Prelude Therapeutics (Inst); Recursion Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Cogent Biosciences